Tonix Pharmaceuticals (NASDAQ:TNXP) Shares Up 13.2% – Should You Buy?

Shares of Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) rose 13.2% during trading on Friday . The company traded as high as $18.40 and last traded at $12.72. Approximately 8,770,194 shares changed hands during mid-day trading, an increase of 471% from the average daily volume of 1,535,123 shares. The stock had previously closed at $11.24.

Analyst Ratings Changes

Separately, StockNews.com assumed coverage on shares of Tonix Pharmaceuticals in a research report on Sunday, February 2nd. They set a “hold” rating on the stock.

Tonix Pharmaceuticals Trading Up 12.5 %

The firm has a 50-day moving average price of $0.82 and a 200 day moving average price of $0.45. The company has a market cap of $2.36 billion, a price-to-earnings ratio of -0.24 and a beta of 2.07. The company has a current ratio of 3.33, a quick ratio of 2.81 and a debt-to-equity ratio of 0.07.

Tonix Pharmaceuticals (NASDAQ:TNXP) last issued its earnings results on Tuesday, November 12th. The company reported ($23.00) EPS for the quarter, beating analysts’ consensus estimates of ($203.00) by $180.00. The company had revenue of $2.82 million during the quarter, compared to the consensus estimate of $2.63 million. Tonix Pharmaceuticals had a negative return on equity of 163.95% and a negative net margin of 1,197.86%. As a group, sell-side analysts forecast that Tonix Pharmaceuticals Holding Corp. will post -17.63 EPS for the current year.

Institutional Investors Weigh In On Tonix Pharmaceuticals

An institutional investor recently bought a new position in Tonix Pharmaceuticals stock. PFG Investments LLC acquired a new stake in shares of Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 218,003 shares of the company’s stock, valued at approximately $72,000. PFG Investments LLC owned approximately 0.12% of Tonix Pharmaceuticals at the end of the most recent quarter. 82.26% of the stock is currently owned by institutional investors.

About Tonix Pharmaceuticals

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.